Capricor Therapeutics vs ProQR Therapeutics
CAPR and PRQR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CAPR and PRQR compare
ProQR Therapeutics scores higher on the StockData Score (7 against 6 for Capricor Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CAPR | PRQR |
|---|---|---|
| Size and price | ||
| Market cap | $483M | – |
| Share price | $8.30 | $1.18 |
| Change, 1 year | 43.8% | −45.4% |
| Change, 5 years | 143% | −83.6% |
| Beta (5Y) | 0.43 | 2.55 |
| Employees | 231 | 59 |
| StockData Score | ||
| Total score | 6 | 7 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 2 (better) |
| Performance score | 0 | 2 (better) |
| Health score | 5 (better) | 3 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 2.0× | – |
| FCF yield | −23.8% | – |
| Growth | ||
| Revenue growth (TTM) | – | 11.4% |
| Profitability | ||
| Operating margin | – | −233% |
| Net margin | – | −229% |
| FCF margin | – | −273% |
| Return on equity | −73.7% | −57.4% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.06 (better) |
| Current ratio | 7.35 (better) | 3.49 |
| Altman Z-score | 0.39 | – |
| Piotroski F-score | 3 (better) | 1 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 67.6% | 57.6% |
| Held by insiders | 1.6% | 37.8% |
| Insider net buying, 12 months | −$8.4M | $1.3M (better) |
| Short interest, % of float | 32.8% | – |
Go deeper
- CAPR stock overview
- CAPR income statement
- CAPR valuation and score
- PRQR stock overview
- PRQR income statement
- PRQR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.